Announced details
Relapsed/refractory AML, high-risk MDS, and MDS/MPN (including CMML)
Overall response rate: 11.8%; median duration of response: 157 days; median time to remission: 29 days; ≥50% reduction in blasts: 10/27 patients overall and 5/14 spliceosome factor mutation-positive patients
42 patients enrolled in the dose-escalation cohort (as of the data cutoff date of 30 April 2026)
NCT05732103 (trial identifier)
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
Yokoyama H et al., Blood Advances 2026；Sato J et al., Clinical Cancer Research 2026
| Item | Details |
|---|---|
| Names of Products / Services Covered | rogocekib（CTX-712） |
| Launch date | Mid-2027 (planned start of the Phase 2 clinical trial) |
| Applicable area | Relapsed/refractory AML, high-risk MDS, and MDS/MPN (including CMML) |
| Registration number and expiry date | NCT05732103 (trial identifier) |
| Quantitative Effects | Overall response rate: 11.8%; median duration of response: 157 days; median time to remission: 29 days; ≥50% reduction in blasts: 10/27 patients overall and 5/14 spliceosome factor mutation-positive patients |
| Usage history | 42 patients enrolled in the dose-escalation cohort (as of the data cutoff date of 30 April 2026) |
| Source | Yokoyama H et al., Blood Advances 2026；Sato J et al., Clinical Cancer Research 2026 |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To determine the recommended dose and target cancer types based on confirmation of the safety and evaluation of the efficacy of the dose-escalation cohort.